NuGen Medical Commences Feasibility Study, Validation and Testing for Semaglutide - "Ozempic(R)"Toronto, Ontario--(Newsfile Corp. - April 10, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") announces it has engaged Basic Pharma Technologies, a pharmaceutical company located in the Netherlands, to perform an assessment and feasibility study, which will include validation testing of semaglutide if administered using NuGen's needle free injection device, InsuJet™. Phase 3 will comprise of QC method and writing and composing and validating, method and validation protocol writing review and effectiveness, method validation study execution and data review, method validation report writing and effectiveness and sample measurement and reporting of sample measurement. For more information, visit www.basicpharma.nlAbout NuGen Medical DevicesNuGen is an emerging specialty medical device company developing the next generation of needle-free technologies and other innovative medical delivery products. This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.

Source: CBC News April 11, 2023 09:22 UTC